Allogene Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Tech

 

• Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ Cells
• Data from Preclinical Study of Cloak™ Technology Highlights Ability to Engineer Allogeneic Cells to Evade Detection by the Host Immune System
• Dagger™ Technology, a Feature of ALLO-316 Currently Being Investigated in a Phase 1 Study for Solid Tumors, Enables Dual AlloCAR T™ Cells to Selectively Eliminate CD70 Positive, Alloreactive Host Immune Cells While Simultaneously Killing CD19-Positive Tumor Cells

https://www.globenewswire.com/news-release/2023/11/03/2773321/0/en/Allogene-Therapeutics-Presents-Preclinical-Data-on-Next-Generation-Cloak-and-Dagger-Technologies-at-the-Society-for-Immunotherapy-of-Cancer-Annual-Meeting.html